EP3784241A4 - Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih - Google Patents

Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih Download PDF

Info

Publication number: EP3784241A4
Authority: EP; European Patent Office
Prior art keywords: compounds useful; hiv integrase; integrase inhibitors; tricyclic compounds; heterocyclic tricyclic
Prior art date: 2018-04-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP19793407.8A

Other languages

German (de)

English (en)

Other versions

EP3784241A1 (fr

Inventor

Tao Yu

James M. Apgar

Alan Whitehead

Yonglian Zhang

Zhiyong Hu

Valerie W. SHURTLEFF

John A. Mccauley

Izzat T. Raheem

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck Sharp and Dohme LLC

Original Assignee

Merck Sharp and Dohme Ltd

Merck Sharp and Dohme LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-04-27

Filing date

2019-04-22

Publication date

2022-01-19

2019-04-22 Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd

2021-03-03 Publication of EP3784241A1 publication Critical patent/EP3784241A1/fr

2022-01-19 Publication of EP3784241A4 publication Critical patent/EP3784241A4/fr

Status Withdrawn legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Quinoline Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

EP19793407.8A 2018-04-27 2019-04-22 Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih Withdrawn EP3784241A4 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201862663377P	2018-04-27	2018-04-27
US201862664527P	2018-04-30	2018-04-30
PCT/US2019/028432 WO2019209667A1 (fr)	2018-04-27	2019-04-22	Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih

Publications (2)

Publication Number	Publication Date
EP3784241A1 EP3784241A1 (fr)	2021-03-03
EP3784241A4 true EP3784241A4 (fr)	2022-01-19

Family

ID=68294232

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP19793407.8A Withdrawn EP3784241A4 (fr)	2018-04-27	2019-04-22	Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih

Country Status (10)

Country	Link
EP (1)	EP3784241A4 (fr)
JP (1)	JP2021522254A (fr)
KR (1)	KR20210005139A (fr)
CN (1)	CN112088005A (fr)
AU (1)	AU2019260608A1 (fr)
BR (1)	BR112020021768A2 (fr)
CA (1)	CA3101180A1 (fr)
MA (1)	MA52367A (fr)
MX (1)	MX2020011317A (fr)
WO (1)	WO2019209667A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11453669B2 (en)	2018-05-31	2022-09-27	Shionogi & Co., Ltd.	Polycyclic pyridone derivative
CA3102063A1 (fr)	2018-05-31	2019-12-05	Shionogi & Co., Ltd.	Derive de carbamoylpyridone polycyclique
ES2989103T3 (es)	2018-06-05	2024-11-25	Merck Sharp & Dohme Llc	Compuestos de heterociclo tricíclico útiles como inhibidores de la integrasa del VIH
IL286328B1 (en)	2019-03-22	2026-04-01	Gilead Sciences Inc	Tricyclic bridging compounds of carbamoylpyridone and their pharmaceutical use
PT4065567T (pt)	2019-11-26	2024-11-08	Gilead Sciences Inc	Processos e intermediários para a preparação de inibidores de mcl1
US12577241B2 (en)	2019-11-28	2026-03-17	Shionogi & Co., Ltd.	Polycyclic pyridopyrazine derivative
CR20220418A (es) *	2020-02-24	2022-10-10	Gilead Sciences Inc	Compuestos tetracíclicos para el tratamiento de infecciones por vih
CA3192145A1 (fr)	2020-09-30	2022-04-07	Gilead Sciences, Inc.	Composes de carbamoylpyridone tricyclique pontes et leurs utilisations
JP7659630B2 (ja)	2020-11-19	2025-04-09	ギリアードサイエンシーズ，インコーポレイテッド	大環状ｍｃｌ１阻害剤を調製するための方法及び中間体
JP7591155B2 (ja)	2021-01-19	2024-11-27	ギリアードサイエンシーズ，インコーポレイテッド	置換ピリドトリアジン化合物及びその使用
TWI856796B (zh)	2022-04-06	2024-09-21	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014183532A1 (fr) *	2013-05-17	2014-11-20	Merck Sharp & Dohme Corp.	Composés hétérocycliques tricycliques fusionnés utiles en tant qu'inhibiteurs de l'intégrase du vih
WO2017113288A1 (fr) *	2015-12-31	2017-07-06	Merck Sharp & Dohme Corp.	Composés hétérocycliques tricycliques condensés utiles en tant qu'inhibiteurs de l'intégrase du vih

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI1441734T1 (sl) *	2001-10-26	2007-08-31	Angeletti P Ist Richerche Bio	Dihidropirimidin karboksamidni inhibitorji HIV-integraze
TW200510425A (en) *	2003-08-13	2005-03-16	Japan Tobacco Inc	Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
US7902182B2 (en) *	2005-11-16	2011-03-08	Bristol-Myers Squibb Company	HIV integrase inhibitors

2019
- 2019-04-22 CA CA3101180A patent/CA3101180A1/fr active Pending
- 2019-04-22 AU AU2019260608A patent/AU2019260608A1/en not_active Abandoned
- 2019-04-22 CN CN201980028504.5A patent/CN112088005A/zh active Pending
- 2019-04-22 MX MX2020011317A patent/MX2020011317A/es unknown
- 2019-04-22 KR KR1020207033726A patent/KR20210005139A/ko not_active Withdrawn
- 2019-04-22 MA MA052367A patent/MA52367A/fr unknown
- 2019-04-22 BR BR112020021768-9A patent/BR112020021768A2/pt not_active Application Discontinuation
- 2019-04-22 EP EP19793407.8A patent/EP3784241A4/fr not_active Withdrawn
- 2019-04-22 WO PCT/US2019/028432 patent/WO2019209667A1/fr not_active Ceased
- 2019-04-22 JP JP2020559525A patent/JP2021522254A/ja active Pending

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014183532A1 (fr) *	2013-05-17	2014-11-20	Merck Sharp & Dohme Corp.	Composés hétérocycliques tricycliques fusionnés utiles en tant qu'inhibiteurs de l'intégrase du vih
WO2017113288A1 (fr) *	2015-12-31	2017-07-06	Merck Sharp & Dohme Corp.	Composés hétérocycliques tricycliques condensés utiles en tant qu'inhibiteurs de l'intégrase du vih

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019209667A1 *
ZUO XIAOFANG ET AL: "Current insights into anti-HIV drug discovery and development: a review of recent patent literature (2014-2017)", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 28, no. 4, 3 April 2018 (2018-04-03), GB, pages 299 - 316, XP055870040, ISSN: 1354-3776, Retrieved from the Internet <URL:http://dx.doi.org/10.1080/13543776.2018.1438410> DOI: 10.1080/13543776.2018.1438410 *

Also Published As

Publication number	Publication date
WO2019209667A1 (fr)	2019-10-31
CA3101180A1 (fr)	2019-10-31
MX2020011317A (es)	2020-11-18
EP3784241A1 (fr)	2021-03-03
CN112088005A (zh)	2020-12-15
AU2019260608A1 (en)	2020-10-29
MA52367A (fr)	2021-03-03
KR20210005139A (ko)	2021-01-13
JP2021522254A (ja)	2021-08-30
BR112020021768A2 (pt)	2021-01-26

Legal Events

Date	Code	Title	Description
2019-11-02	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2020-10-28	TPAC	Observations filed by third parties	Free format text: ORIGINAL CODE: EPIDOSNTIPA
2021-01-29	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2021-01-29	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2021-03-03	17P	Request for examination filed	Effective date: 20201127
2021-03-03	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2021-03-03	AX	Request for extension of the european patent	Extension state: BA ME
2021-08-04	RAV	Requested validation state of the european patent: fee paid	Extension state: MA Effective date: 20201127 Extension state: MD Effective date: 20201127 Extension state: TN Effective date: 20201127
2022-01-19	A4	Supplementary search report drawn up and despatched	Effective date: 20211216
2022-01-19	RIC1	Information provided on ipc code assigned before grant	Ipc: C07D 487/16 20060101ALI20211210BHEP Ipc: A61K 31/4985 20060101AFI20211210BHEP
2022-10-19	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: MERCK SHARP & DOHME LLC
2023-02-10	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN
2023-03-15	18W	Application withdrawn	Effective date: 20230208

Publication	Publication Date	Title
EP3752144A4 (fr)	2021-09-22	Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
MA52367A (fr)	2021-03-03	Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
EP3801543A4 (fr)	2022-03-02	Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
EP3548031A4 (fr)	2020-06-03	Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
MA52754A (fr)	2021-04-14	Composés hétérocycliques tricycliques en tant qu'activateurs de sting
MA55198A (fr)	2022-01-12	Composés tricycliques fusionnés utiles en tant qu'agents anticancéreux
EP2997033A4 (fr)	2016-10-26	Composés hétérocycliques tricycliques fusionnés utiles en tant qu'inhibiteurs de l'intégrase du vih
EP3377065A4 (fr)	2019-06-12	Dérivés de pyridotriazine spirocyclique utiles en tant qu'inhibiteurs de l'intégrase du vih
MA53377A (fr)	2021-06-02	Composés de pyridin-2-one utiles en tant qu'antagonistes de smarca2
EP3377066A4 (fr)	2019-05-29	Dérivés de pyridotriazine amido-substitués utiles en tant qu'inhibiteurs de l'intégrase du vih
MA43528A (fr)	2018-11-07	Composés hétérocycliques tricycliques condensés à titre d'inhibiteurs de l'intégrase du vih
MA51878A (fr)	2020-12-30	Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
EP3389380A4 (fr)	2019-07-31	Dérivés de quinolizine spirocycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
MA52486A (fr)	2021-03-10	Pyridazinones utilisés en tant qu'inhibiteurs de parp7
EP3601239A4 (fr)	2020-05-13	Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
MA43169A (fr)	2018-09-12	Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA46196A (fr)	2021-05-19	Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal
MA51438A (fr)	2021-04-14	Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA45377A (fr)	2019-04-24	Composés hétérocycliques en tant qu'agents antibacteriens
EP3755311A4 (fr)	2021-11-10	Indane-amines utiles en tant qu'antagonistes de pd-l1
MA49888A (fr)	2020-06-24	Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
EP3883570A4 (fr)	2022-07-13	Hétérocycles fonctionnalisés utiles en tant qu'agents antiviraux
MA45375A (fr)	2019-04-24	Composés hétérocycliques utilisés en tant qu'agents antibacteriens
MA45189A (fr)	2019-04-10	Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
EP3733671A4 (fr)	2021-06-09	Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase